MCID: RTN015
MIFTS: 53

Retinal Cancer

Categories: Cancer diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Retinal Cancer

MalaCards integrated aliases for Retinal Cancer:

Name: Retinal Cancer 12 15
Malignant Neoplasm of Retina 12 73
Retinal Neoplasms 44 73
Malignant Retinal Neoplasm 12
Malignant Tumor of Retina 12
Neoplasm of Retina 12
Retinal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4645
ICD10 33 C69.2
ICD9CM 35 190.5
MeSH 44 D019572
NCIt 50 C3216 C4800

Summaries for Retinal Cancer

MalaCards based summary : Retinal Cancer, also known as malignant neoplasm of retina, is related to retinoblastoma and vulvar adenocarcinoma. An important gene associated with Retinal Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Signaling by GPCR. The drugs Etoposide and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina,... more...

Related Diseases for Retinal Cancer

Diseases related to Retinal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 retinoblastoma 27.2 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
2 vulvar adenocarcinoma 11.0 RB1 TP53
3 glioblastoma proneural subtype 11.0 CDK4 CDK6
4 breast papillomatosis 11.0 CCND1 CDKN2A
5 brain stem astrocytic neoplasm 11.0 CDKN2A TP53
6 ewing's family of tumors 10.9 CDK4 CDKN2A RB1
7 zika virus infection 10.9 MDM2 TP53
8 oral leukoplakia 10.9 CCND1 CDKN2A TP53
9 endometrial squamous cell carcinoma 10.8 CCND1 CDK6 CDKN2A
10 spindle cell lipoma 10.8 CDK4 MDM2 RB1
11 unilateral retinoblastoma 10.8 RB1 RBL1
12 pre-malignant neoplasm 10.8 CCND1 CDKN2A TP53
13 ring chromosome 7 10.8 CDK4 MDM2 TP53
14 gastrointestinal system benign neoplasm 10.8 CCND1 CDKN2A TP53
15 bladder carcinoma in situ 10.8 CCND3 CDKN2A TP53
16 chondromyxoid fibroma 10.8 CCND1 CDKN1A CDKN2A
17 penile cancer 10.8 CCND1 CDKN2A TP53
18 infiltrating angiolipoma 10.8 CDK4 CDKN2A MDM2
19 pharynx cancer 10.8 CCND1 CDKN2A TP53
20 periosteal osteogenic sarcoma 10.8 CDK4 MDM2 TP53
21 actinic cheilitis 10.8 CDKN1A MDM2 TP53
22 megaesophagus 10.8 CDKN2A MYC TP53
23 atypical lipomatous tumor 10.8 CDK4 CDKN2A MDM2
24 well-differentiated liposarcoma 10.8 CDK4 CDKN2A MDM2
25 small cell sarcoma 10.7 CDK4 MDM2 TP53
26 tongue cancer 10.7 CDKN1A CDKN2A TP53
27 cervical adenocarcinoma 10.7 CDKN1A CDKN2A TP53
28 embryonal sarcoma 10.7 CDK4 MDM2 TP53
29 splenic diffuse red pulp small b-cell lymphoma 10.7 CCND3 TP53
30 undifferentiated embryonal sarcoma of the liver 10.7 CDK4 MDM2
31 cell type benign neoplasm 10.7 CCND1 CDKN2A TP53
32 hepatic angiomyolipoma 10.7 MYC RB1
33 gallbladder adenoma 10.7 CDKN2A RB1
34 connective tissue cancer 10.7 CDK4 MDM2 TP53
35 oral cancer 10.7 CCND1 CDKN2A TP53
36 malignant fibrous histiocytoma of bone 10.7 CDK4 MDM2 MYC
37 cellular schwannoma 10.7 CDKN2A MDM2 TP53
38 myxoid liposarcoma 10.7 CDK4 MDM2 TP53
39 melanoma, cutaneous malignant 1 10.6 CDK4 CDK6 CDKN2A TP53
40 gliosarcoma 10.6 CCND3 CDK4 RB1 TP53
41 schneiderian carcinoma 10.6 CDKN2A RBL2 TP53
42 histiocytoma 10.6 CDK4 MDM2 TP53
43 keratinizing squamous cell carcinoma 10.6 CDKN2A TP53
44 periosteal chondrosarcoma 10.6 CDK4 CDKN2A MDM2 RB1
45 male reproductive organ cancer 10.6 CCND1 MYC TP53
46 inflammatory myofibroblastic tumor 10.6 CCND1 MDM2 TP53
47 ischemic fasciitis 10.6 CCND1 CDK4 CDKN2A MDM2
48 bile duct carcinoma 10.6 CCND1 MYC TP53
49 malignant mesenchymoma 10.6 CDK4 CDKN1A MDM2 TP53
50 grade iii astrocytoma 10.6 CDK4 CDKN2A MDM2 TP53

Graphical network of the top 20 diseases related to Retinal Cancer:



Diseases related to Retinal Cancer

Symptoms & Phenotypes for Retinal Cancer

GenomeRNAi Phenotypes related to Retinal Cancer according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 CDK2 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 MDM2 CDK2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 CCND1 MDM2 MYC CDK2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 MDM2 CDK2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.36 E2F1 MYC RBL1 RBL2 CDK6 CDKN1B
28 Decreased viability GR00221-A-2 10.36 E2F1 RBL1 CDK6
29 Decreased viability GR00221-A-3 10.36 MYC CDKN2A
30 Decreased viability GR00221-A-4 10.36 CDKN2A CDK6
31 Decreased viability GR00301-A 10.36 CDK6
32 Decreased viability GR00402-S-2 10.36 E2F1 MYC RBL1 RBL2 CDK6 CDKN1B
33 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.7 CDK2 CDKN1A CDKN1B E2F3 MDM2 TP53
34 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.67 CDK1 CDK2 CDK4 CDKN1B
35 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.58 CDK1 CDK4 CDKN1B
36 Reduced mammosphere formation GR00396-S 9.5 CCND1 CCND3 CDK4 CDK6 E2F2 MDM2
37 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CDK2 CDKN1A CDKN2A E2F1 RB1 TP53
38 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CCND1 CDK1 CDK2 CDKN1A CDKN2A E2F1

MGI Mouse Phenotypes related to Retinal Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 CCND1 CDK1 CDK2 CDK4 CDK6 CDKN1A
2 endocrine/exocrine gland MP:0005379 10.58 E2F2 E2F3 E2F4 MDM2 MYC RB1
3 cardiovascular system MP:0005385 10.56 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
4 growth/size/body region MP:0005378 10.55 E2F2 E2F3 E2F4 MDM2 MYC RB1
5 embryo MP:0005380 10.51 CDK1 CDK2 RB1 RBL1 RBL2 TP53
6 mortality/aging MP:0010768 10.51 CDKN2A E2F1 E2F2 E2F3 E2F4 MDM2
7 homeostasis/metabolism MP:0005376 10.5 CCND1 CCND3 CDK1 CDK2 CDK4 CDKN1A
8 immune system MP:0005387 10.49 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
9 behavior/neurological MP:0005386 10.48 CCND1 CCND3 CDK4 CDKN1A CDKN1B CDKN2A
10 hematopoietic system MP:0005397 10.48 CDKN1B CDKN2A E2F1 E2F2 E2F4 MDM2
11 integument MP:0010771 10.45 CCND1 CDK2 CDK4 CDKN1A CDKN1B CDKN2A
12 neoplasm MP:0002006 10.43 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
13 digestive/alimentary MP:0005381 10.42 E2F3 E2F4 MDM2 MYC RB1 RBL1
14 liver/biliary system MP:0005370 10.37 TP53 CCND3 CDK1 CDK2 CDK4 CDK6
15 craniofacial MP:0005382 10.36 CDKN1A CDKN1B E2F1 E2F4 MDM2 MYC
16 muscle MP:0005369 10.31 CDKN2A E2F1 MDM2 MYC RB1 RBL1
17 nervous system MP:0003631 10.3 RBL1 RBL2 TP53 CCND1 CDK4 CDKN1A
18 normal MP:0002873 10.25 CCND1 CCND3 CDK1 CDK4 E2F1 E2F2
19 adipose tissue MP:0005375 10.24 CDKN1A CDKN1B E2F1 E2F3 MYC RB1
20 hearing/vestibular/ear MP:0005377 10.24 RBL1 RBL2 TP53 CDKN1A CDKN1B E2F1
21 reproductive system MP:0005389 10.19 CDK1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
22 no phenotypic analysis MP:0003012 10.13 CDKN1A CDKN1B CDKN2A E2F3 MDM2 MYC
23 limbs/digits/tail MP:0005371 10.08 CDKN1A MDM2 MYC RB1 RBL1 RBL2
24 renal/urinary system MP:0005367 9.97 TP53 CDK4 CDKN1A CDKN1B E2F2 MDM2
25 respiratory system MP:0005388 9.97 CDKN1B CDKN2A E2F1 E2F2 E2F3 E2F4
26 pigmentation MP:0001186 9.91 CDK4 CDKN1B CDKN2A MDM2 MYC RB1
27 skeleton MP:0005390 9.77 CCND1 CDKN1A CDKN1B CDKN2A E2F1 E2F3
28 vision/eye MP:0005391 9.5 CCND1 CCND3 CDK1 CDK2 CDK4 CDKN1A

Drugs & Therapeutics for Retinal Cancer

Drugs for Retinal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Nicotine Approved Phase 4 54-11-5 942 89594
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Hydroxyitraconazole Phase 4
17 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Cytochrome P-450 CYP3A Inhibitors Phase 4
20 Cytochrome P-450 Enzyme Inhibitors Phase 4
21 Antifungal Agents Phase 4,Phase 2,Phase 1
22
Cisplatin Approved Phase 3,Phase 2,Not Applicable 15663-27-1 84093 441203 2767
23
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
24
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
25
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
26
Topotecan Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 119413-54-6, 123948-87-8 60700
27
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
28
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
29
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
30
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
31
Doxil Approved June 1999 Phase 3,Phase 2 31703
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
34 cadexomer iodine Phase 3,Phase 2,Phase 1
35 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
37 Micronutrients Phase 3,Phase 2
38 Anesthetics Phase 3,Phase 2,Not Applicable,Early Phase 1
39 Trace Elements Phase 3,Phase 2
40 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Estrogen Antagonists Phase 3,Phase 2,Phase 1
43 Estrogens Phase 3,Phase 2,Phase 1
44 Anti-Infective Agents, Local Phase 3,Phase 2
45 Aromatase Inhibitors Phase 3,Phase 2,Phase 1
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48
Ranibizumab Approved Phase 2,Phase 1 347396-82-1 459903
49
Fulvestrant Approved, Investigational Phase 2,Phase 1 129453-61-8 104741 17756771
50
Metformin Approved Phase 2 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
4 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
5 Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma Completed NCT00072384 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
6 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3 carboplatin;vincristine sulfate
7 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
8 Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma Recruiting NCT03475121 Phase 3
9 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3 3 cycles chemotherapy;6 cycles chemotherapy
10 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 cisplatin;cyclophosphamide;etoposide;carboplatin;vincristine sulfate;thiotepa
11 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine + Topotecan;Vincristine + Carboplatin + Etoposide;Vincristine + Cyclophosphamide + Doxorubicin;Vincristine+Carboplatin+Etoposide
12 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
13 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) Active, not recruiting NCT01740427 Phase 3 PD-0332991;Letrozole;Placebo;Letrozole
14 Efficacy Study of Lucentis in the Treatment of Retinoblastoma Unknown status NCT01899066 Phase 2 Lucentis, chemotherapy;chemotherapy
15 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2 Carboplatin;VP-16
16 Chemotherapy in Treating Patients With Retinoblastoma Completed NCT00002675 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;mesna;vincristine sulfate
17 Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Completed NCT00002794 Phase 2 carboplatin;vincristine sulfate
18 Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Completed NCT00901238 Phase 1, Phase 2
19 Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Completed NCT00004006 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride
20 Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. Completed NCT01291017 Phase 2 PD0332991
21 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
22 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease Completed NCT02140814 Phase 2
23 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Completed NCT00003173 Phase 2 thiotepa
24 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
25 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
26 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
27 An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. Completed NCT00555906 Phase 2 Bortezomib;Dexamethasone;PD 0332991
28 Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Completed NCT01433913 Phase 2 metformin hydrochloride
29 Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer Completed NCT00721409 Phase 2 PD 0332991;letrozole;letrozole
30 Intra-arterial Chemotherapy for Children With Retinoblastoma Recruiting NCT00906113 Phase 1, Phase 2 Intra-arterial injection of melphalan;Injection of melphalan into the ophthalmic artery
31 Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma Recruiting NCT01783535 Phase 2 vincristine;topotecan;filgrastim;PEG-filgrastim;carboplatin;etoposide;cyclophosphamide;MESNA;doxorubicin
32 Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Recruiting NCT02870907 Phase 2 Etoposide;Vincristine;Carboplatin;Vincristine;Cyclophosphamide;Carboplatin;Etoposide;Carboplatin;Thiotepa;Vincristine;Cyclophosphamide;Carboplatin;Etoposide;Thiotepa
33 Conservative Treatments of Retinoblastoma Recruiting NCT02866136 Phase 2 VP16, carboplatin;Melphalan;VP16, carboplatin, vincristin;Carboplatin + laser day 1 (chemothermotherapy);intravitreal Melphalan (local treatment)
34 Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Recruiting NCT03130439 Phase 2 Abemaciclib
35 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast Recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
36 Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Recruiting NCT02555189 Phase 1, Phase 2 Enzalutamide;Ribociclib
37 Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Recruiting NCT03024489 Phase 1, Phase 2 Palbociclib;Palbociclib;Palbociclib;Palbociclib;Cetuximab
38 Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC Recruiting NCT03184090 Phase 2 Palbociclib;Endocrine therapy (non IMP)
39 Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Active, not recruiting NCT00110110 Phase 2 Carboplatin;Cyclosporine;Etoposide;vincristine sulfate
40 A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Active, not recruiting NCT02059213 Phase 2 Ibrance;Bicalutamide;Zoladex;Lupron Depot
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced B Active, not recruiting NCT01684215 Phase 2 PD-0332991;PD-0332991;letrozole;PD-0332991;letrozole
43 Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Terminated NCT01293539 Phase 2 Melphalan hydrochloride
44 Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Terminated NCT01857752 Phase 2 Temozolomide
45 Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Terminated NCT00432445 Phase 2
46 Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Terminated NCT01393769 Phase 2 Melphalan
47 Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy Terminated NCT02334527 Phase 2 Palbociclib
48 A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Terminated NCT01919229 Phase 2 LEE011 (ribociclib);letrozole
49 Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Withdrawn NCT01151748 Phase 2
50 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate

Search NIH Clinical Center for Retinal Cancer

Cochrane evidence based reviews: retinal neoplasms

Genetic Tests for Retinal Cancer

Anatomical Context for Retinal Cancer

MalaCards organs/tissues related to Retinal Cancer:

41
Retina, Eye, Prostate, Bone, Bone Marrow, Heart, Myeloid

Publications for Retinal Cancer

Articles related to Retinal Cancer:

# Title Authors Year
1
Maintenance of retinal cancer stem cell-like properties through long-term serum-free culture from human retinoblastoma. ( 21573498 )
2011
2
Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen. ( 8392328 )
1993

Variations for Retinal Cancer

Cosmic variations for Retinal Cancer:

9
(show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 6
2 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 6
3 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 6
4 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 6
5 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 6
6 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 6
7 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 6
8 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 6
9 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 6
10 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 6
11 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 6
12 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 6
13 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 6
14 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 6
15 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 6
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 6
17 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 6
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 6
19 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 6
20 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 6
21 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 6
22 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 6
23 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 6
24 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 6
25 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 6
26 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 6
27 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 6
28 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 6
29 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 6
30 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 6
31 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 6
32 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 6
33 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 6
34 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 6
35 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 6
36 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 6
37 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 6
38 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 6
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 6
40 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 6
41 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 6
42 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 6
43 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 6
44 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 6
45 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 6

Expression for Retinal Cancer

Search GEO for disease gene expression data for Retinal Cancer.

Pathways for Retinal Cancer

Pathways related to Retinal Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.42 CCND1 CCND3 CDK1 CDK2 CDK4 CDKN1A
2
Show member pathways
14.3 CCND1 CCND3 CDK1 CDK2 CDK4 CDKN1A
3
Show member pathways
14.1 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
4
Show member pathways
13.96 CDK1 CDK2 CDKN1A CDKN1B CDKN2A E2F1
5
Show member pathways
13.96 CCND1 CCND3 CDK1 CDK2 CDK4 CDKN1A
6
Show member pathways
13.78 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
7
Show member pathways
13.42 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
8
Show member pathways
13.3 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9
Show member pathways
13.26 CDK1 CDK2 CDKN1A CDKN1B CDKN2A E2F1
10
Show member pathways
13.24 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
11 13.21 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
12
Show member pathways
13.17 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
13
Show member pathways
13.14 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
14
Show member pathways
13.11 CCND1 CDK1 CDK2 CDK4 CDKN1A CDKN1B
15
Show member pathways
13.02 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
16
Show member pathways
13.02 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
17
Show member pathways
13.01 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
18 12.99 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
19
Show member pathways
12.98 CCND1 CDKN1B E2F1 E2F2 E2F3 E2F4
20
Show member pathways
12.92 CCND1 E2F1 E2F3 MYC TP53
21
Show member pathways
12.91 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
22 12.91 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
23
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
24 12.87 CCND1 CDK6 CDKN1A CDKN1B CDKN2A E2F1
25
Show member pathways
12.81 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
26
Show member pathways
12.8 CDK1 CDK2 CDKN1A CDKN1B MDM2 TP53
27 12.8 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
28
Show member pathways
12.8 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
29
Show member pathways
12.72 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
30
Show member pathways
12.71 CCND1 CDKN1B MDM2 MYC RB1 TP53
31 12.71 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
32
Show member pathways
12.69 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
33
Show member pathways
12.67 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
34
Show member pathways
12.61 E2F1 E2F2 E2F3 E2F4 RB1
35 12.61 CDK1 CDK2 CDKN1A CDKN1B MDM2 MYC
36 12.58 CCND1 CCND3 CDK4 CDKN1A CDKN2A E2F1
37 12.54 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
38
Show member pathways
12.51 CDK2 CDKN1A CDKN1B RB1 TP53
39 12.48 CCND1 CDK2 CDK4 E2F1 MDM2 MYC
40 12.46 CCND1 CDKN1A MDM2 MYC TP53
41
Show member pathways
12.46 CCND1 CCND3 CDK4 E2F1 E2F2 E2F4
42
Show member pathways
12.45 CDK1 CDK2 E2F1 RB1
43
Show member pathways
12.43 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
44 12.42 CDKN1A CDKN1B MDM2 MYC TP53
45 12.42 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
46
Show member pathways
12.42 CCND1 CDK2 CDK4 CDKN1A E2F1 E2F2
47 12.41 CCND1 CDK1 CDKN1A E2F4 MYC RBL1
48 12.39 CCND1 CDK1 CDK2 CDK4 CDKN1B E2F1
49 12.37 CCND1 CCND3 CDKN1A CDKN1B CDKN2A MDM2
50 12.37 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F1

GO Terms for Retinal Cancer

Cellular components related to Retinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.95 CDK4 CDKN1A CDKN2A MDM2 MYC RBL2
2 nucleoplasm GO:0005654 9.93 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
3 transcription factor complex GO:0005667 9.81 CDK2 CDK4 E2F1 E2F2 E2F3 E2F4
4 nuclear chromatin GO:0000790 9.73 E2F1 E2F4 MYC TP53
5 chromatin GO:0000785 9.62 CDK4 RB1 RBL1 RBL2
6 Rb-E2F complex GO:0035189 9.37 E2F1 RB1
7 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.17 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
8 nucleus GO:0005634 10.26 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6

Biological processes related to Retinal Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.99 CDKN1A CDKN1B CDKN2A TP53
2 cellular response to hypoxia GO:0071456 9.99 E2F1 MDM2 MYC TP53
3 response to toxic substance GO:0009636 9.98 CDK1 CDK4 CDKN1A MDM2
4 response to organic substance GO:0010033 9.97 CCND1 CDK2 CDK4 CDKN1A
5 regulation of G2/M transition of mitotic cell cycle GO:0010389 9.94 CDK1 CDK2 CDK6 CDKN2A
6 cellular response to organic cyclic compound GO:0071407 9.91 CDKN1B MDM2 MYC
7 Ras protein signal transduction GO:0007265 9.91 CDK2 CDKN1A CDKN2A RB1 TP53
8 G1/S transition of mitotic cell cycle GO:0000082 9.91 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9 negative regulation of epithelial cell proliferation GO:0050680 9.9 CDK6 CDKN1B RB1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.9 CDKN1A RB1 RBL1 RBL2
11 protein kinase B signaling GO:0043491 9.89 CDKN1A CDKN1B MDM2
12 negative regulation of cell cycle GO:0045786 9.89 CDK6 CDKN1B RB1
13 animal organ regeneration GO:0031100 9.89 CCND1 CDK1 CDK4 CDKN1A
14 response to organonitrogen compound GO:0010243 9.87 CCND1 CDK1 CDKN1A
15 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.87 E2F1 E2F2 TP53
16 cell cycle arrest GO:0007050 9.87 CDK6 CDKN1A CDKN1B CDKN2A MYC RB1
17 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.86 CCND1 CCND3 CDKN1B
18 cellular response to gamma radiation GO:0071480 9.85 CDKN1A MDM2 TP53
19 regulation of mitotic cell cycle GO:0007346 9.85 CDK1 CDKN1A MYC RB1 RBL1 RBL2
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.84 CDKN1A CDKN1B CDKN2A
21 response to X-ray GO:0010165 9.84 CCND1 CDKN1A TP53
22 positive regulation of G2/M transition of mitotic cell cycle GO:0010971 9.83 CCND1 CDK1 CDK4
23 negative regulation of cell cycle arrest GO:0071157 9.83 CCND1 CDK4 MDM2
24 positive regulation of fibroblast proliferation GO:0048146 9.83 CDK4 CDK6 CDKN1A E2F1 MYC
25 negative regulation of phosphorylation GO:0042326 9.81 CDKN1A CDKN1B CDKN2A
26 replicative senescence GO:0090399 9.8 CDKN1A CDKN2A TP53
27 positive regulation of cell cycle GO:0045787 9.8 CCND1 CDK4 CDKN1B MDM2 MYC
28 mitotic G1 DNA damage checkpoint GO:0031571 9.78 CCND1 CDK2 TP53
29 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.75 CDK4 CDK6 CDKN2A
30 cellular response to estrogen stimulus GO:0071391 9.74 MDM2 MYC
31 response to hyperoxia GO:0055093 9.74 CDK4 CDKN1A
32 determination of adult lifespan GO:0008340 9.74 PRDM2 TP53
33 response to magnesium ion GO:0032026 9.74 CCND1 MDM2
34 regulation of insulin receptor signaling pathway GO:0046626 9.74 CCND3 CDK4
35 histone phosphorylation GO:0016572 9.74 CDK1 CDK2
36 cellular response to antibiotic GO:0071236 9.73 CDKN1B MDM2
37 amyloid fibril formation GO:1990000 9.73 CDKN2A MDM2
38 negative regulation of monocyte differentiation GO:0045656 9.73 CDK6 MYC
39 re-entry into mitotic cell cycle GO:0000320 9.72 CCND1 MYC
40 signal transduction by p53 class mediator GO:0072331 9.72 CDKN1A TP53
41 negative regulation of fat cell proliferation GO:0070345 9.72 E2F1 E2F3
42 cellular response to xenobiotic stimulus GO:0071466 9.72 E2F1 RB1
43 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.72 CDK4 MYC
44 lens fiber cell apoptotic process GO:1990086 9.71 E2F1 E2F2
45 negative regulation of cyclin-dependent protein kinase activity GO:1904030 9.71 CDKN1A CDKN1B
46 regulation of lipid kinase activity GO:0043550 9.71 RB1 RBL1 RBL2
47 cellular response to actinomycin D GO:0072717 9.69 MDM2 TP53
48 negative regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0071930 9.69 E2F1 RB1
49 regulation of cell cycle GO:0051726 9.65 CCND1 CCND3 CDK2 CDK4 CDKN1A E2F1
50 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.28 CDK1 CDK2 CDKN1A CDKN1B E2F1 E2F4

Molecular functions related to Retinal Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.98 CCND1 CDK1 CDK2 CDK4 CDK6
2 kinase activity GO:0016301 9.97 CCND1 CDK1 CDK2 CDK4 CDK6 CDKN1A
3 protein dimerization activity GO:0046983 9.92 E2F1 E2F2 E2F3 E2F4 MYC
4 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 9.89 E2F2 E2F3 E2F4 PRDM2 TP53
5 core promoter binding GO:0001047 9.81 E2F1 E2F2 E2F3 RB1
6 transcription factor binding GO:0008134 9.81 CCND1 CDKN2A E2F1 E2F2 E2F4 MYC
7 RNA polymerase II activating transcription factor binding GO:0001102 9.75 RB1 RBL1 RBL2
8 promoter-specific chromatin binding GO:1990841 9.71 E2F4 RBL1 RBL2 TP53
9 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.65 CDKN1A CDKN1B CDKN2A
10 RNA polymerase II regulatory region DNA binding GO:0001012 9.61 RB1 RBL1 RBL2
11 histone kinase activity GO:0035173 9.57 CDK1 CDK2
12 cyclin-dependent protein kinase activity GO:0097472 9.56 CDK1 CDK2
13 disordered domain specific binding GO:0097718 9.56 CDKN2A MDM2 RB1 TP53
14 cyclin binding GO:0030332 9.43 CDK1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
15 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.23 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
16 protein binding GO:0005515 10.32 CCND1 CCND3 CDK1 CDK2 CDK4 CDK6
17 DNA binding GO:0003677 10.25 CDKN2A E2F1 E2F2 E2F3 E2F4 MYC
18 DNA binding transcription factor activity GO:0003700 10.14 E2F1 E2F2 E2F3 E2F4 MYC PRDM2
19 protein kinase binding GO:0019901 10 CCND1 CCND3 CDKN1A CDKN1B CDKN2A E2F1

Sources for Retinal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....